[go: up one dir, main page]

NO20090165L - Combination preparations including bifeprunox and L-DOPA - Google Patents

Combination preparations including bifeprunox and L-DOPA

Info

Publication number
NO20090165L
NO20090165L NO20090165A NO20090165A NO20090165L NO 20090165 L NO20090165 L NO 20090165L NO 20090165 A NO20090165 A NO 20090165A NO 20090165 A NO20090165 A NO 20090165A NO 20090165 L NO20090165 L NO 20090165L
Authority
NO
Norway
Prior art keywords
bifeprunox
dopa
preparations including
combination preparations
simultaneous
Prior art date
Application number
NO20090165A
Other languages
Norwegian (no)
Inventor
Gustaaf Johan Marie Van Scharrenburg
Martinus Th M Tulp
Andrew C Mccreary
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20090165L publication Critical patent/NO20090165L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår anvendelsen av et kombinasjonspreparat av bifeprunox eller dets N-oksid, eller farmakologisk akseptable salter av disse forbindelsene, for samtidig, separat eller sekvensiell anvendelse i behandlingen av lidelser som krever gjenvinning av dopaminergisk funksjon, spesielt Parkinsons sykdom og "Restless Leg"-syndrom.The invention relates to the use of a combination preparation of bifeprunox or its N-oxide, or pharmacologically acceptable salts of these compounds, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function, in particular Parkinson's disease and Restless Leg syndrome. .

NO20090165A 2006-06-16 2009-01-12 Combination preparations including bifeprunox and L-DOPA NO20090165L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405206P 2006-06-16 2006-06-16
EP06115587 2006-06-16
PCT/EP2007/055956 WO2007144422A2 (en) 2006-06-16 2007-06-15 Combination preparations comprising bifeprunox and l-dopa

Publications (1)

Publication Number Publication Date
NO20090165L true NO20090165L (en) 2009-01-12

Family

ID=38691894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090165A NO20090165L (en) 2006-06-16 2009-01-12 Combination preparations including bifeprunox and L-DOPA

Country Status (9)

Country Link
EP (1) EP2037964A2 (en)
JP (1) JP2009539942A (en)
KR (1) KR20090033871A (en)
AU (1) AU2007259256A1 (en)
CA (1) CA2654557A1 (en)
EA (1) EA014576B1 (en)
IL (1) IL195493A0 (en)
NO (1) NO20090165L (en)
WO (1) WO2007144422A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110027817A (en) * 2008-06-30 2011-03-16 노파르티스 아게 Parkinson's disease combination with MBRL modulator
ITMI20100260A1 (en) * 2010-02-19 2011-08-20 Giulio Scigliano PHARMACEUTICAL COMPOSITION CONTAINING A DRUG TO REDUCE THE SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
HRP20161402T1 (en) * 2010-10-15 2016-12-30 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
MY169068A (en) * 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
JP6567049B2 (en) * 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド Carbidopa and L-dopa prodrugs and methods for their use
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
CA3117983A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA

Also Published As

Publication number Publication date
KR20090033871A (en) 2009-04-06
WO2007144422A2 (en) 2007-12-21
EA014576B1 (en) 2010-12-30
JP2009539942A (en) 2009-11-19
EA200970022A1 (en) 2009-06-30
CA2654557A1 (en) 2007-12-21
IL195493A0 (en) 2009-09-01
AU2007259256A1 (en) 2007-12-21
WO2007144422A3 (en) 2008-03-13
EP2037964A2 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20090165L (en) Combination preparations including bifeprunox and L-DOPA
NO20082768L (en) Levodopa prodrug mesylate, compositions and uses thereof
JO2756B1 (en) 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof
DK2023918T3 (en) Cyclosporins for the treatment and prevention of ocular disorders
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
MX2009011359A (en) Pyrimidinone derivatives and methods of use thereof.
SI2142193T1 (en) 1-?á2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL?åPIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
DK2004225T3 (en) Programs for vaccination with meningococcal conjugates
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
NO20065878L (en) Therapeutic compounds
BRPI0816255A2 (en) Pharmaceutical product, use of the product, method for the prophylaxis or treatment of diseases, and pharmaceutically acceptable composition.
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
BR0309185A (en) Beta-mimetic drug and a new anticholinergic
DK2244703T3 (en) Drug and the preparation and use thereof in the treatment of painful neuropathies
DK2175877T3 (en) Use of mutated antithrombin for the treatment or prevention of coagulation disorders
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2010005545A (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure.
MX2008014247A (en) Aqueous tobacco leaf extract, uses thereof in the treatment of dependence.
NO20090164L (en) Combination preparations including SLV308 and an L-DOPA
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
WO2007144699A3 (en) Process for the preparation of alfuzosin
UA94466C2 (en) Combination preparations comprising slv308 and a l-dopa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application